Takeda Gmbh

Nycomed Gmbh

Astrazeneca Ab

Christof Zitt

Armin Hatzelmann

Degenhard Marx

Hans-Peter Kley

Beate Schmidt

Geert Jan Sterk

Dieter Flockerzi

Andrea Wohlsen

Anke Heuser

Ulrich Kautz

Hermann Tenor

Rolf-Peter Hummel

Christian Scheufler

Martin Feth

Wiro M P B Menge

Clemens Braun

Sarvesh S Patel

Thomas Maier

Martin Viertelhaus

Johannes A M Christiaans

Deborah Ockert

Torsten Dunkern

Raimund Külzer

Jens Christoffers

Anna Rosiak

Christian Hesslinger

Stefan Fischer

Andreas Pahl

Steffen Weinbrenner

Jürgen Volz

Hiteshkumar D Jain

Ragna Hussong

Ewald Benediktus

Imre Schlemminger

Juergen Volz

Thomas Stengel

Anna Christoffers

Rainer Boer

Harald Ohmer

Alexander Mann

Manojkumar Tiwari

Arati Prabhu

Sandip Gavade

Mahindra Makhija

Christiane Praechter

Simone Hartung

Manuela Hessmann

Angelika Hoffmeyer

Ashish Keche

Maria Vittoria Chiesa

Jens Prof Dr Christoffers

Martin P Feth

Johannes Barsig

Wiro MPB Menge

Herrmann Tenor

Tobias Kanacher

Hans Christof Holst

Josef Stadlwieser

The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Pyrazolone-derivatives and their use as PDE-4 inhibitors

The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

EP2 receptor agonists

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Pyrazolone derivatives as PDE4 inhibitors

The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.

The compounds of formula I in which R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-oxa-10-aza-phenanthrenes

The compounds of formula I in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-thia-10-aza-phenanthrene derivatives

Growing community of inventors

Constance, Germany

Christof Zitt